SEC filing · 10-Q

Angiodynamics Inc: Quarterly report

AngioDynamics grew revenue and expanded gross margins in the first quarter of fiscal 2027 while reducing its net loss.

Filed October 8, 2026 · period ended August 31, 2026

Mixed for the company

What the numbers say

Revenue rose 6.9% to $80.9M versus the same quarter last year (6.6% down on the previous quarter); operating margin widened from -14.1% to -9.0%; diluted EPS -$0.17 versus -$0.26; cash fell by $19.9M to $34M; diluted share count up 2.1% (dilution).

Compared with the same period a year earlier, from the figures Angiodynamics Inc reported to the SEC.

What happened

Revenue increased by 6.9% to $80.9 million, led by 13.2% growth in the Med Tech segment.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Angiodynamics Inc

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.